- Direct arylation under catalysis of an oxime-derived palladacycle: Search for a phosphane-free method
-
A phosphane-free method for the direct arylation of benzothiazole by employing oxime-derived palladacycle 1 as a catalyst was developed. The new catalyst system can be used for 2-arylations by using aryl bromides and iodides. In addition, this method is especially suitable for the intramolecular direct coupling of bromo-and iodoamides, as well aschloroamides, to achieve a rapid synthesis of benzo[c]phenanthridine alkaloids. Direct arylation reactions under catalysis of an oxime-derived palladacycle were investigated. This phosphane-free method is applicable for the 2-arylation of benzothiazole and is especially suitable for the intramolecular direct coupling of bromo-and iodoamides, as well as chloroamides, to achieve rapid synthesis of benzo[c]phenanthridine alkaloids. Copyright
- Zhang, Guofu,Zhao, Xiaobao,Yan, Yunbing,Ding, Chengrong
-
supporting information; experimental part
p. 669 - 672
(2012/03/27)
-
- Chemical process for making angiotesin II antagonist compounds
-
The invention provides a novel chemical process for the manufacture of quinoline, pyridine and imidazole derivatives of the formula IV wherein Q, Y 1 and Y 2 have the various meanings defined herein, and their non-toxic salts, which are angiotensin II inhibitors. The process involves the removal of an electron-deficient phenyl group or a pyridyl or pyrimidyl group from a compound of the formula VI as defined herein.
- -
-
-
- Chemical process and intermediates used therein
-
The invention provides a novel chemical process for the manufacture of certain imidazo[4,5-b]pyridine derivatives of the formula I wherein R 1, R 2, R 3 and R 4 have the various meanings defined herein, and their non-toxic salts, which are angiotensin II inhibitors. The process involves the removal of an electron-deficient phenyl group or a pyridyl or pyrimidyl group from a compound of the formula II as defined herein. Certain of the intermediates are novel and are provided as a further feature of the invention.
- -
-
-
- 1,6-NAPHTHYRIDONE DERIVATIVES HAVING ANGIOTENSIN II ANTAGONIST ACTIVITY
-
The invention concerns pharmaceutically useful compounds of the formula I, in which R 1, R 2, R 3, R 4, Ra, Rb, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
- -
-
-
- PYRIDINYL COMPOUNDS WHICH ARE USEFUL AS ANGIOTENSIN II ANTAGONISTS
-
The invention concerns pharmaceutically useful compounds of the formula I, in which R 1, R 2, R 3, R 4, R 5, R. sup.6, R 7, Rz, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment. STR1
- -
-
-
- Heterocyclic boron compounds as intermediates for angiotensin II antagonists
-
The invention concerns novel boron compounds of the formula IV, in which Q, Y 1, G 1 and G 2 have the various meanings defined herein, and their acid and base addition salts. The said compounds are useful in the manufacture of certain quinoline, pyridine and imidazole derivatives which have angiotensin II inhibitory activity. The invention also provides novel processes for the production of the quinoline, pyridine and imidazole derivatives. STR1
- -
-
-
- Angiotensin II antagonizers which are condensed pyridine derivatives
-
The invention concerns pharmaceutically useful novel compounds of the formula I, in which R1, R2, R3, R4, R5, R6, R7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
- -
-
-